Alpha1-Proteinase Inhibitor (Human) (Zemaira)

Key Messages

• CADTH recommends that Zemaira be reimbursed for the treatment of severe alpha₁-proteinase inhibitor (A₁-PI) deficiency if certain conditions are met.
• Zemaira should only be covered to treat patients with severe A₁-PI deficiency (e.g., genotypes PiZZ, PiZ(null), Pi(null,null), PiSZ) and clinical evidence of emphysema who are nonsmokers for at least 6 months.
• Zemaira should only be reimbursed if prescribed by a respirologist and the cost of Zemaira is reduced.